Sanofi India500674Dividend news update

Interim dividend of Rs. 75 per equity share declared; Q3 2026 results approved

Board declared an interim dividend of Rs. 75/- per equity share (face value Rs. 10/-) for 2026.

By ScoutQuest · Thu 29 Oct 2026, 6:46 PM IST · 2 min read

Interim Dividend: Rs. 75/- per equity share (face value Rs. 10/-) for 2026
Record Date: Thursday, 5th November 2026
Q3 2026 Revenue and Profit: Revenue ₹ 4,917 million vs ₹ 4,754 million; Profit ₹ 1,167 million vs ₹ 760 million; EPS ₹ 50.67 vs ₹ 32.99

The Board declared an interim dividend of Rs. 75/- per equity share of face value Rs. 10/- each for the financial year 2026, to be paid within the stipulated timelines.
The record date is Thursday, 5th November 2026. Members on the Register of Members on that date, and beneficial owners as per NSDL and CDSL details at the close of business that day, are covered.

Revenue from operations for Q3 2026 was 4,917, against 4,754 in Q3 2025. For the nine months, it was 14,017 against 14,176.
Profit before exceptional item and tax was 1,577, against 1,296 a year earlier.
Profit for the period was 1,167, against 760.
Basic and diluted earnings per share (not annualised) was ₹ 50.67, against ₹ 32.99.
The prior-year quarter carried an exceptional item of ₹273 million relating to personnel separation costs; the current quarter shows no exceptional item.
Total expenses were 3,395 for Q3 2026 against 3,507 in Q3 2025.

Domestic net sales growth of +2% and total net sales growth of 4% over Q3 2025.
The insulin portfolio grew 9% in Q3 2026; the company reports a 55% market share in the diabetes injectable segment, with 14% growth in YTD 2026 on a value basis.
The public sector business grew 85%, attributed to new accounts opened for innovative analogue segments.
Profit before tax and exceptional items is stated at INR 158 crores, against INR 130 crores in Q3 2025; profit before tax as a percentage of net sales improved to 34% from 29%.
Operating expenses (employee cost plus other expenses) declined 8% year on year. The improvement is attributed to a favourable product mix, a one-off reversal of provisions and cost efficiencies.
Export sales are described as having delivered double-digit growth.
Partnership revenues across Cardiovascular, Oral anti-Diabetes and Central Nervous System segments were broadly stable, and the release says continued focus is needed to strengthen performance.

Price Waterhouse & Co Chartered Accountants LLP carried out a limited review of the results and stated that nothing came to its attention indicating the statement is not prepared in accordance with the applicable accounting standards.
The results were reviewed by the Audit Committee and approved by the Board on 29th October 2026, and the company reports a single segment, Pharmaceutical Business.

Also from Sanofi India

29 Oct 2026

29 Oct 2026

29 Oct 2026